Biomarin Pharmaceutical (BMRN) Deferred Taxes (2010 - 2026)
Biomarin Pharmaceutical's (BMRN) quarterly Deferred Taxes came in at $9.2 million in Q1 2026, down 67.57% YoY from $28.4 million in Q1 2025, and up 1404.08% on a QoQ basis from $613000.0 in Q4 2025.
Biomarin Pharmaceutical (BMRN) Deferred Taxes (2010 - 2026) Analysis & Trends
Biomarin Pharmaceutical (BMRN) has 17 years of Deferred Taxes data on file, last reported at $9.2 million in Q1 2026.
- Quarterly Deferred Taxes fell 67.57% year-over-year to $9.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29.5 million (down 64.95% YoY) and the FY2025 annual result came in at $48.7 million, down 13.12% from the prior year.
- Deferred Taxes rose to $9.2 million in Q1 2026, from $613000.0 in the prior quarter.
- In the past five years, Deferred Taxes ranged from a high of $42.4 million in Q4 2024 to a low of -$51.3 million in Q4 2022.
- A 5-year average of $999176.5 and a median of $613000.0 in 2025 frame the typical range for Deferred Taxes.
- Annual changes were most pronounced in 2022 — Deferred Taxes plunged 1330.99% — and 2025, when it surged 9875.09%.
- Tracing BMRN's Deferred Taxes over 5 years: stood at -$51.3 million in 2022, then soared by 51.61% to -$24.8 million in 2023, then surged by 270.61% to $42.4 million in 2024, then tumbled by 98.55% to $613000.0 in 2025, then surged by 1404.08% to $9.2 million in 2026.
- The last three Deferred Taxes figures came in at $9.2 million (Q1 2026), $613000.0 (Q4 2025), and -$13.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -69.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 194.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -137,876.64 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.66 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Biomarin Pharmaceutical | 13.04 Bn | 12.16 Bn | 786.91 Mn | -6.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.96 Mn |
| Mar 31, 2026 | 9.22 Mn |
| Dec 31, 2025 | 613,000.00 |
| Sep 30, 2025 | -13.65 Mn |
| Jun 30, 2025 | 33.34 Mn |
| Mar 31, 2025 | 28.43 Mn |
| Dec 31, 2024 | 42.39 Mn |
| Sep 30, 2024 | 12.17 Mn |
| Jun 30, 2024 | 1.25 Mn |
| Mar 31, 2024 | 285,000.00 |
| Dec 31, 2023 | -24.84 Mn |
| Sep 30, 2023 | -15.03 Mn |
| Jun 30, 2023 | 1.25 Mn |
| Mar 31, 2023 | -6.36 Mn |
| Dec 31, 2022 | -51.34 Mn |
| Sep 30, 2022 | -4.20 Mn |
| Jun 30, 2022 | -1.35 Mn |
| Mar 31, 2022 | 4.80 Mn |
| Dec 31, 2021 | -3.59 Mn |
| Sep 30, 2021 | -13.22 Mn |